NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Bonvalot, Sylvie; Rutkowski, Piotr; Thariat, Juliette; Carrère, Sébastien; Ducassou, A.; Sunyach, Marie‐Pierre; Ágoston, Péter; Hong, Angela; Mervoyer, A.; Rastrelli, Marco; Moreno, Víctor; Li, Rubi K.; Tiangco, B.; Herráez, Antonio Casado; Gronchi, Alessandro; Mangel, László; Sy-Ortin, Teresa; Hohenberger, Peter; Baère, Thierry De; Cesne, Axel Le; Helfre, Sylvie; Sâada-Bouzid, Esma; Borkowska, Aneta; Anghel, Rodica; Co, Ann; Gebhart, Michaël; Kantor, G.; Montero, Á.; Loong, Herbert H.; Vergés, Ramona; Lapeire, Lore; Dema, Sorin; Kacsó, Gabriel; Austen, Lyn; Moureau-Zabotto, Laurence; Servois, Vincent; Wardelmann, Eva; Terrier, Philippe; Lazar, Alexander J.; Bovée, Judith V.M.G.; Péchoux, C. Le; Papaï, Z.

doi:10.1016/s1470-2045(19)30326-2

Cited by 303 publications

(224 citation statements)

References 34 publications

Supporting

Mentioning

222

Contrasting

Unclassified

Order By: Relevance

Section: New Approvalsmentioning

confidence: 99%

“…NBTXR3/Hensify is a 50 nm crystalline hafnium oxide nanoparticle with negatively charged phosphate coating, developed and marketed by Nanobiotix . NBTXR3/Hensify enhances external radiotherapy via a physical mode of action that relies on hafnium's natural radioenhancing properties . Specifically, the interaction between ionizing radiation and hafnium facilitates a higher energy deposit as compared to ionizing radiation without hafnium interaction; this results in the generation of significantly more electrons and increases radiation‐mediated cell death from standard radiation oncology procedures .…”

Section: New Approvalsmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles in the clinic: An update

Anselmo

Mitragotri

2019

Bioengineering & Transla Med

1,210

943

View full text Add to dashboard Cite

Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of Bioengineering & Translational Medicine in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.

show abstract

Section: New Approvalsmentioning

confidence: 99%

Section: New Approvalsmentioning

confidence: 99%

Nanoparticles in the clinic: An update

Anselmo

Mitragotri

2019

Bioengineering & Transla Med

1,210

943

View full text Add to dashboard Cite

show abstract

“…Various nanoparticles have entered clinical application. NBTRX3 oxide hafnium nanoparticles by Nanobiotix have demonstrated clinical efficacy in sarcomas in a phase 3 trial [161]. They increased the complete pathological response rate by 2-fold and the complete resection margin (R0) rate.…”

Section: Nanoparticle-enhanced Radiationmentioning

confidence: 99%

Hadrontherapy Interactions in Molecular and Cellular Biology

Thariat

Valable

Laurent

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

The resistance of cancer cells to radiotherapy is a major issue in the curative treatment of cancer patients. This resistance can be intrinsic or acquired after irradiation and has various definitions, depending on the endpoint that is chosen in assessing the response to radiation. This phenomenon might be strengthened by the radiosensitivity of surrounding healthy tissues. Sensitive organs near the tumor that is to be treated can be affected by direct irradiation or experience nontargeted reactions, leading to early or late effects that disrupt the quality of life of patients. For several decades, new modalities of irradiation that involve accelerated particles have been available, such as proton therapy and carbon therapy, raising the possibility of specifically targeting the tumor volume. The goal of this review is to examine the up-to-date radiobiological and clinical aspects of hadrontherapy, a discipline that is maturing, with promising applications. We first describe the physical and biological advantages of particles and their application in cancer treatment. The contribution of the microenvironment and surrounding healthy tissues to tumor radioresistance is then discussed, in relation to imaging and accurate visualization of potentially resistant hypoxic areas using dedicated markers, to identify patients and tumors that could benefit from hadrontherapy over conventional irradiation. Finally, we consider combined treatment strategies to improve the particle therapy of radioresistant cancers.

show abstract

“…One example is intratumoral hafnium oxide nanoparticles, which are being tested in the clinic for enhancing RT against cancer types such as soft tissue sarcoma and head and neck cancer. [9][10][11] Another widely studied high-Z element is gold.…”

Section: Introductionmentioning

confidence: 99%

Ultrathin Gold Nanowires to Enhance Radiation Therapy

Bai

Wang

Lee³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Radiation therapy is a main treatment option for cancer. Due to normal tissue toxicity, radiosensitizers are commonly used to enhance RT. In particular, heavy metal or high-Z materials, such as gold nanoparticles, have been investigated as radiosensitizers. So far, however, the related studies have been focused on spherical gold nanoparticles. In this study, we assessed the potential of ultra-thin gold nanowires as a radiosensitizer, which is the first time. Methods: Gold nanowires were synthesized by the reduction of HAuCl4 in hexane. The as-synthesized gold nanowires were then coated with a layer of PEGylated phospholipid to be rendered soluble in water. Spherical gold nanoparticles coated with the same phospholipid were also synthesized as a comparison. Gold nanowires and gold nanospheres were first tested in solutions for their ability to enhance radical production under irradiation. They were then incubated with 4T1 cells to assess whether they could elevate cell oxidative stress under irradiation. Lastly, gold nanowires and gold nanoparticles were intratumorally injected into a 4T1 xenograft model, followed by irradiation applied to tumors (3 Gy/per day for three days). Tumor growth was monitored and compared. Results: Our studies showed that gold nanowires are superior to gold nanospheres in enhancing radical production under X-ray radiation. In vitro analysis found that the presence of gold nanowires caused elevated lipid peroxidation and intracellular oxidative stress under radiation. When tested in vivo, gold nanowires plus irradiation led to better tumor suppression than gold nanospheres plus radiation. Moreover, gold nanowires were found to be gradually reduced to shorter nanowires by glutathione, which may benefit fractionated radiation. Conclusion: Our studies suggest that gold nanowires are a promising type of radiosensitizer that can be safely injected into tumors to enhance radiotherapy. While the current study was conducted in a breast cancer model, the approach can be extended to the treatment of other cancer types.

show abstract

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Cited by 303 publications

References 34 publications

Nanoparticles in the clinic: An update

Nanoparticles in the clinic: An update

Hadrontherapy Interactions in Molecular and Cellular Biology

Ultrathin Gold Nanowires to Enhance Radiation Therapy

Contact Info

Product

Resources

About